A/Prof Alexander Menzies

BSc(Med), MBBS (Hons), FRACP, PhD

Visit specialist website

Languages: English


  • Cancer

Areas of Interest

  • Melanoma
  • Breast cancer

Mater Hospital, North Sydney, NSW

Sydney Medical Oncology
Suites 3-4, The Poche Centre
40 Rocklands Rd
Wollstonecraft NSW 2065

T: (02) 9911 7258

F: (02) 9922 7139

E: SMO_reception@melanoma.org.au


Associate Professor Menzies (AM) is a Medical Oncologist and Associate Professor of Melanoma Medical Oncology at Melanoma Institute Australia (MIA), The University of Sydney, and Royal North Shore and Mater Hospitals.

His main research interests are clinical trials of new systemic therapies for melanoma, biomarkers of response and resistance to systemic therapy, and immunotherapy-related toxicity. He conducts investigator-led and sponsored clinical trials, Chairs the Department of Cancer Medicine at the Mater Hospital and the Melanoma and Skin Group for COSA and serves as Faculty member for the ESMO and Steering Committee member for SMR. He co-established an international clinical research collaboration network between several major melanoma centres leading to high impact original research publications, and is co-lead of the clinical trials working party of the international neoadjuvant melanoma consortium.
A/Prof Menzies has been extremely productive at this early stage of his career (PhD 2015), with first or senior author papers in Nature Medicine, Lancet Oncology, and Annals of Oncology, among others, in addition to original papers in Nature, Nature Communications, Nature Medicine, and Cancer Cell. In the last 5 years he has published 140 articles gathering over 11,000 citations, and has a H-index of 58 (GS). He was awarded the Clarivate Web of Science – Highly Cited Researcher (top 1% of researchers in the world by citation) in 2020, and was the recipient of the 2018 NSW Premier’s Award - Outstanding Cancer Research Fellow (<5 years). He has been awarded a National Health and Medical Research Council Investigator Grant for 2022 (5 years).
He has led work into the successful introduction of immunotherapy into non-clinical trial populations, such as those with autoimmune disease and chronic viral infections, and introduced immunotherapy for melanoma patients with brain metastases and as neoadjuvant therapy.

Better and fairer care. Always.

In a rapidly transforming world, St Vincent's has created a refreshed vision and strategy to help shape Australia's health and aged care future.